Loading…
5 companies · GEL, thousands · columns ordered by revenue
| Company | Sector | EBITDA margin · FY 2024 | Percentile | Sector n |
|---|---|---|---|---|
| Sinevo Sakartvelo | Healthcare Services | 26.9% | 87th pct | 268 |
| Medical Center Cito | Healthcare Services | 22.4% | 81st pct | 268 |
| Mega-Lab | Healthcare Services | 14.4% | 64th pct | 268 |
| Center of Urology and N… | Healthcare Services | 7.6% | 44th pct | 268 |
| Mrcheveli | Healthcare Services | — | no FY data | 268 |
Percentile is within each company's own sector across the whole FY2024 cross-section (1st–100th; higher = larger value). Companies with no sector, or no filing for the year, are not ranked.
Only 4 of 5 peers filed FY2024. Switch to FY2023 (5 of 5).
| Ratio — FY 2024 | Mega-Lab | Medical Center Cito | Sinevo Sakartvelo | Center of Urology and N… | Mrcheveli |
|---|---|---|---|---|---|
| Margins | |||||
| Gross Margin | 32.8% | 79.3% | 55.1% | 79.5% | — |
| EBITDA Margin | 14.4% | 22.4% | 26.9% | 7.6% | — |
| EBITDAR | 3,352 | 3,761 | 6,029 | 1,092 | — |
| EBITDAR Margin | 15.1% | 22.4% | 37.4% | 7.6% | — |
| EBIT Margin | 9.0% | 15.5% | 21.7% | -0.7% | — |
| Net Profit Margin | 6.1% | 11.8% | 24.2% | -3.2% | — |
| Operating Expense % of Sales | 18.4% | 56.9% | 28.2% | 71.9% | — |
| Returns | |||||
| Return on Assets (ROA) | 4.7% | 14.9% | 46.0% | -2.1% | — |
| Return on Equity (ROE) | 7.8% | 32.4% | 47.6% | -3.5% | — |
| ROIC [EBIT / Invested Capital] | |||||
| 8.2% |
| 27.3% |
| 110.0% |
| -0.6% |
| — |
| Leverage & debt balances | |||||
| Debt-to-Assets | 25.5% | 37.0% | 0.0% | 11.9% | — |
| Debt-to-Equity | 0.43x | 0.80x | 0.00x | 0.20x | — |
| Debt-to-EBITDA | 2.31x | 1.31x | 0.00x | 2.34x | — |
| Equity-to-Assets | 59.4% | 45.9% | 96.6% | 60.5% | — |
| Net Debt | 7,186 | 3,435 | -5,014 | 2,003 | — |
| Cash & Equivalents | 200 | 1,477 | 5,014 | 549 | — |
| Total Debt | 7,386 | 4,913 | N/A | 2,552 | — |
| Liquidity & working capital | |||||
| Current Ratio | 0.78x | 0.91x | 21.06x | 0.62x | — |
| Quick Ratio | 0.55x | 0.74x | 21.06x | 0.47x | — |
| Cash Ratio | 0.02x | 0.37x | 17.31x | 0.09x | — |
| Total Current Assets | 7,555 | 3,626 | 6,097 | 3,889 | — |
| Total Current Liabilities | 9,648 | 3,963 | 290 | 6,262 | — |
| Inventory | 2,237 | 691 | N/A | 930 | — |
| Trade Receivables | 3,797 | 1,023 | 182 | 2,169 | — |
| Trade Payables | 3,524 | 1,996 | 279 | 4,055 | — |
| Net Working Capital | -2,093 | -337 | 5,808 | -2,373 | — |
| Net Working Capital % of Revenue | -9.4% | -2.0% | 36.0% | -16.6% | — |
| Trade Working Capital | 2,510 | -282 | -97 | -956 | — |
| Trade Working Capital % of Revenue | 11.3% | -1.7% | -0.6% | -6.7% | — |
| Change in Trade Working Capital | N/A | N/A | N/A | N/A | — |
| Turnover & efficiency | |||||
| Inventory Turnover | 6.66x | 5.01x | N/A | 3.15x | — |
| Days Inventory Outstanding (DIO) | 54.8 | 72.8 | N/A | 116.0 | — |
| Receivables Turnover | 5.84x | 16.41x | 88.50x | 6.59x | — |
| Days Sales Outstanding (DSO) | 62.5 | 22.2 | 4.1 | 55.4 | — |
| Payables Turnover | 4.23x | 1.74x | 25.90x | 0.72x | — |
| Days Payable Outstanding (DPO) | 86.3 | 210.2 | 14.1 | 505.7 | — |
| Cash Conversion Cycle | 31.0 days | -115.2 days | -10.0 days | -334.3 days | — |
| Asset Turnover | 0.77x | 1.26x | 1.90x | 0.67x | — |
| Cash flow & dividends | |||||
| Operating Cash Flow | 234 | 2,785 | N/A | 1,451 | — |
| Free Cash Flow (OCF − Capex proxy) | -331 | 1,562 | N/A | 55 | — |
| Cash Conversion (OCF / EBITDA) | 7.3% | 74.1% | N/A | 132.9% | — |
| Dividends Declared | 0 | 724 | N/A | 0 | — |
| Dividend Payout Ratio | 0.0% | 36.6% | N/A | N/A | — |